Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease
- PMID: 28857501
- DOI: 10.1111/1751-2980.12540
Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease
Abstract
Inflammatory bowel diseases (IBD), comprising of ulcerative colitis and Crohn's disease, are inflammatory disorders of the gastrointestinal tract characterized by chronically relapsing mucosal inflammation. Neutrophils, as the effector cells of acute inflammation, have long been reported to play a role in the maintenance of intestinal homeostasis and pathogenesis of IBD. At the early stage of mucosal inflammation in patients with IBD, neutrophils flood into intestinal mucosa, phagocytose pathogenic microbes, and promote mucosal healing and resolution of inflammation. However, large numbers of neutrophils infiltrating in the inflamed mucosa and accumulating in the epithelia cause damage of mucosal architecture, compromised epithelial barrier and production of inflammatory mediators. In this review we discuss the critical roles of neutrophils in modulating innate and adaptive immune responses in intestinal mucosa, and, importantly, clarify the potential roles of neutrophils related to their production of inflammatory mediators, transenthothelial and transepithelial migration into intestinal mucosa, and the underlying mechanisms in regulating mucosal inflammation of IBD. Moreover, we also describe a new subset of neutrophils (i.e., CD177+ neutrophils) and illustrate its protective role in modulating intestinal mucosal immune responses in IBD.
Keywords: CD177; immunomodulation; inflammatory bowel diseases; neutrophils.
© 2017 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
Similar articles
-
Dual role of CD177 + neutrophils in inflammatory bowel disease: a review.J Transl Med. 2024 Sep 2;22(1):813. doi: 10.1186/s12967-024-05539-3. J Transl Med. 2024. PMID: 39223577 Free PMC article. Review.
-
CD177+ neutrophils as functionally activated neutrophils negatively regulate IBD.Gut. 2018 Jun;67(6):1052-1063. doi: 10.1136/gutjnl-2016-313535. Epub 2017 May 3. Gut. 2018. PMID: 28468761
-
Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease.Int J Mol Sci. 2021 Jul 16;22(14):7618. doi: 10.3390/ijms22147618. Int J Mol Sci. 2021. PMID: 34299236 Free PMC article. Review.
-
Immunopathology of inflammatory bowel disease.World J Gastroenterol. 2014 Jan 7;20(1):6-21. doi: 10.3748/wjg.v20.i1.6. World J Gastroenterol. 2014. PMID: 24415853 Free PMC article. Review.
-
Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis.Adv Biol Regul. 2017 Jan;63:140-155. doi: 10.1016/j.jbior.2016.11.001. Epub 2016 Nov 14. Adv Biol Regul. 2017. PMID: 27866974 Free PMC article. Review.
Cited by
-
Dual role of CD177 + neutrophils in inflammatory bowel disease: a review.J Transl Med. 2024 Sep 2;22(1):813. doi: 10.1186/s12967-024-05539-3. J Transl Med. 2024. PMID: 39223577 Free PMC article. Review.
-
The analysis of fecal calprotectin as a diagnostic marker for anastomotic leakage after rectal cancer surgery: a pilot study.J Surg Case Rep. 2023 Jul 29;2023(7):rjad432. doi: 10.1093/jscr/rjad432. eCollection 2023 Jul. J Surg Case Rep. 2023. PMID: 37525751 Free PMC article.
-
Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases.Immun Inflamm Dis. 2023 Jul;11(7):e934. doi: 10.1002/iid3.934. Immun Inflamm Dis. 2023. PMID: 37506139 Free PMC article. Review.
-
Food-specific IgGs Are Highly Increased in the Sera of Patients with Inflammatory Bowel Disease and Are Clinically Relevant to the Pathogenesis.Intern Med. 2018 Oct 1;57(19):2787-2798. doi: 10.2169/internalmedicine.9377-17. Epub 2018 May 18. Intern Med. 2018. PMID: 29780153 Free PMC article. Clinical Trial.
-
Molecular targets associated with ulcerative colitis and the benefits of atractylenolides-based therapy.Front Pharmacol. 2024 May 27;15:1398294. doi: 10.3389/fphar.2024.1398294. eCollection 2024. Front Pharmacol. 2024. PMID: 38860174 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources